Market Surveillance and Counterfeit Medical Consumables Control in Myanmar

1. Key takeaways

Under the guidance of the Ministry of Health, the Myanmar FDA systematically regulates the market to ensure the quality, authenticity and safety of products in circulation. As the problem of counterfeit medical consumables has risen, the authority has markedly strengthened substantive review of free sale certificates (FSC) and notarised documents. Any discrepancy in product name or address between the company registration, the FSC and the letter of authorisation will immediately trigger a request for clarification and can cause delays of several months.

GRZAN note: this trend shifts the centre of gravity of compliance work from the quantity of documents to the consistency of documents. Companies should build a cross-document field comparison table and complete a field-by-field verification before submission. The governance focus can be recorded as: 3 key documents, 1 trend of intensified review, and 1 set of field comparison mechanisms. The essential change is that a document which is individually correct can still fail review, because the review now runs across documents and not merely within each one, so the comparison table is not an optional nicety but the control that matches the review actually being performed.

2. Legal basis

The table below summarises the supervising authority, the driver of the intensified review, the trigger conditions and the consequences that follow. The pattern is consistent: a market-level problem has been answered not with a new law but with a sharper review of the documents that already exist.

3. Expert insights

Insight 1: the focus of document review is consistency, not completeness. Even a complete set of documents will trigger clarification if the fields do not match across documents. This reorders the usual preparation checklist: companies habitually ask whether every required document is present, while in Myanmar the sharper question is whether every shared field, such as the legal name and the registered address, is spelled identically everywhere it appears. Completeness without consistency still fails.

Insight 2: the cross-comparison of three key documents is the lever of the review. The company registration documents, the FSC and the letter of authorisation must correspond verbatim in product name, model and address. The comparison is mechanical, which is exactly why it is dangerous: an automated or clerical check on the authority’s side does not weigh context, and a single character of difference in a transliterated name is enough to fire the trigger.

Insight 3: delays can reach several months, and the cost is significant. A delay of that magnitude is sufficient to disrupt an entire supply plan, from order confirmation to delivery scheduling. The loss is not limited to the administrative effort of responding to the clarification; it propagates into inventory coverage, contractual delivery dates and the credibility the company has built with its distributors. Since the trigger is a mismatch of a few characters, the ratio of effort to prevention is extreme: minutes of comparison protect months of schedule.

Insight 4: the counterfeit problem has raised the threshold of authenticity verification. The verifiability of documents now matters more than it did before. Issuing bodies must be identifiable and their signatures or seals must be checkable, because the review is no longer satisfied by the formal presence of a certificate; it asks whether the certificate can actually be confirmed against its issuer. Companies that obtain certificates from intermediaries without direct access to the issuing body will find this harder to demonstrate, which is reason enough to change the sourcing of documents before the authority asks.

Insight 5: systematic market supervision means inspection is a routine activity. Companies must maintain continuous conformity rather than aiming for a one-time pass. The supervision described here does not end when the registration certificate is issued; it continues across the life of the product in the market, which means the internal controls that produced a consistent dossier at submission must keep operating as documents are renewed, amended or reissued. A comparison table built once and never revisited degrades exactly as fast as the documents it tracks.

4. Practical recommendations

• Build a cross-document field comparison table. Cover the company registration, the FSC and the letter of authorisation, listing every shared field and the exact value that must appear in each document.
• Complete field-by-field verification before submission. Leave no spelling differences; verify names, models and addresses against the source documents, not against memory or a previous submission.
• Ensure that all documents come from verifiable issuing bodies. This facilitates authenticity checks and shortens any later clarification round, because verification can be done at once rather than requested piecemeal.
• Update every document in step whenever any information changes. Establish a linkage mechanism so that a change of address or a renaming cannot leave one document carrying the old value.
• Reserve buffer time for possible clarification requests. Do not schedule projects on the assumption of zero deficiency responses; plan the calendar so that a multi-month clarification would not break the supply chain.

5. Verification checklist

• □ A cross-document field comparison table has been established
• □ Field-by-field verification before submission has been completed
• □ The issuing bodies of the documents have been confirmed as verifiable
• □ A linkage mechanism between information changes and document updates has been established
• □ Buffer time for clarification requests has been reserved
• □ The authorised representative has been confirmed to retain complete records
• □ The items have been incorporated into the registration ledger

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com